Tetrazine-based metal-organic frameworks

Jiang, Hongfei; Gong, Qiuyu; Zhang, Renshuai; Yuan, Hongye

doi:10.1016/j.ccr.2023.215501

Cited by 2 publications

(1 citation statement)

References 180 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concept of nitroreductase activable agents for tumor theranostic purposes encompasses two main components: therapeutic agents and diagnostic probes. Therapeutic agents, such as chemotherapeutic drugs or cytotoxic compounds, are conjugated to a nitroreductase-sensitive moiety that is cleaved upon enzymatic activation within tumor cells ( Jiang et al, 2021b ; Jiang et al, 2023a ; Jiang et al, 2023b ; Zhang et al, 2023b ; Zhao et al, 2023 ). This targeted release of active therapeutics enhances the efficacy of cancer treatment while minimizing systemic toxicity ( Knox et al, 1995 ; Güngör et al, 2019 ; Güngör et al, 2020 ; Tokay et al, 2020 ).…”

Section: Distinct Advantages Of Nitroreductase Activable Agentsmentioning

confidence: 99%

Recent advances and applications of nitroreductase activable agents for tumor theranostic

Shang,

Yu,

Wang

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Nitroreductase activable agents offer a personalized and targeted approach to cancer theranostics by selectively activating prodrugs within the tumor microenvironment. These agents enable non-invasive tumor imaging, image-guided drug delivery, and real-time treatment monitoring. By leveraging the enzymatic action of tumor-specific nitroreductase enzymes, cytotoxic drugs are delivered directly to cancer cells while minimizing systemic toxicity. This review highlights the key features, mechanisms of action, diagnostic applications, therapeutic potentials, and future directions of nitroreductase activable agents for tumor theranostics. Integration with imaging modalities, advanced drug delivery systems, immunotherapy combinations, and theranostic biomarkers shows promise for optimizing treatment outcomes and improving patient survival in oncology. Continued research and innovation in this field are crucial for advancing novel theranostic strategies and enhancing patient care. Nitroreductase activable agents represent a promising avenue for personalized cancer therapy and have the potential to transform cancer diagnosis and treatment approaches.

show abstract